Market taxonomy by types classifies the Assistive Reproductive market according to the technological or therapeutic modality employed, each generating a discrete revenue slice. Hormonal stimulation protocols—including gonadotropin‑releasing hormone (GnRH) agonists and antagonists—represent roughly 30 % of spend, as they are prerequisite for most oocyte‑retrieval procedures and command recurring drug sales. Gamete retrieval and processing (aspiration, sperm selection, ICSI) accounts for about 22 %, reflecting the intensive labor and equipment costs of operating operating‑room suites and embryology labs. Embryo culture systems (sequential media, time‑lapse imaging) contribute 15 %, driven by premium pricing for optimized developmental environments and data‑driven incubation. Embryo transfer technologies—including catheter design and ultrasound‑guided placement—hold 12 % of the market, with incremental value derived from improved implantation rates. Genetic testing services (PGT‑A, PGT‑M, PGT‑SR) occupy 13 %, as laboratories charge per‑embryo analysis and insurers increasingly reimburse. Cryopreservation infrastructure (vitrification devices, storage tanks) rounds out the segment with 8 %, supporting both elective and medical‑necessity cases. Together, these type‑based slices explain the distribution of capital and consumable expenditures that underpin the overall market size.
